Toinv

I guess any bagholders who are still long and strong in this play are fools - so that makes at least two of us - we were played. The last time Mr McCaffrey took questions was the investment forum and the questions were selected by him on the fly and only partially answered by him in a contrived and closed fund-raising format. I would hope that he gets grilled by the BOD. Shareholders deserve to know what happened to the Covid project. Most likely it was not an improvement over Paxlovid and the SOC but who knows? Apabetalone supposedly was to be a dual mechanism cure-all for Covid-19 - all variants - and should have EUA in the Canada and US by now - isn't that why we are into Eversana for 10MM? What happened for them to pull the plug - safety issues, adverse reactions, lack of efficacy? We deserve to know the truth. More and more ???s but we never seem to get any answers

Resverlogix is at a pivotal stage of development. I figure they need at least 100MM to clean up their debts, secure the IP and keep operating thru another Covid and BOM trial. Go it alone? That will never happen - he had his chance and blew it. Do you wish to keep this captain on the payroll to navigate another trial? This company needs new leadership and a significant capital infusion. How will they accomplish it? If Mr McCaffrey stays at the helm RVX will eventually be folded into Hepalink - hopefully BP sees this epigenetic platform and BET inhibition as a future commercial opportunity. The bom trial and btd award and ongoing Zenith ph2 oncology trials may have derisked RVX and Zenith enough for them to take it on as a package- unfortunately Mr McCaffery mucked it up with Royalty Preferred Shares and sales of market rights to Hepalink, Israel and Eversana. If they do take it on the price will by discounted for the aforementioned revenue committments.

Time to turn the page.

Chicagoest